Literature DB >> 26555014

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds.

Chen-Jei Tai1, Chia-Lin Li2, Cheng-Jeng Tai3, Chien-Kai Wang4, Liang-Tzung Lin5.   

Abstract

Cell-based systems are useful for discovering antiviral agents. Dissecting the viral life cycle, particularly the early entry stages, allows a mechanistic approach to identify and evaluate antiviral agents that target specific steps of the viral entry. In this report, the methods of examining viral inactivation, viral attachment, and viral entry/fusion as antiviral assays for such purposes are described, using hepatitis C virus as a model. These assays should be useful for discovering novel antagonists/inhibitors to early viral entry and help expand the scope of candidate antiviral agents for further drug development.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26555014      PMCID: PMC4692676          DOI: 10.3791/53124

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  42 in total

Review 1.  Screening methods for influenza antiviral drug discovery.

Authors:  Colm Atkins; Carrie W Evans; E Lucile White; James W Noah
Journal:  Expert Opin Drug Discov       Date:  2012-03-22       Impact factor: 6.098

2.  Time and temperature dependence of influenza virus membrane fusion at neutral pH.

Authors:  A M Haywood; B P Boyer
Journal:  J Gen Virol       Date:  1986-12       Impact factor: 3.891

Review 3.  Advances in the structure-based design of the influenza A neuraminidase inhibitors.

Authors:  Petar M Mitrasinovic
Journal:  Curr Drug Targets       Date:  2010-03       Impact factor: 3.465

4.  Sendai virus membrane fusion: time course and effect of temperature, pH, calcium, and receptor concentration.

Authors:  A M Haywood; B P Boyer
Journal:  Biochemistry       Date:  1982-11-23       Impact factor: 3.162

Review 5.  Update on the current status of cytomegalovirus vaccines.

Authors:  Heungsup Sung; Mark R Schleiss
Journal:  Expert Rev Vaccines       Date:  2010-11       Impact factor: 5.217

Review 6.  Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management.

Authors:  P G Arduino; S R Porter
Journal:  Oral Dis       Date:  2006-05       Impact factor: 3.511

Review 7.  Respiratory syncytial virus prevention and therapy: past, present, and future.

Authors:  Melvin Wright; Giovanni Piedimonte
Journal:  Pediatr Pulmonol       Date:  2010-11-23

8.  Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate.

Authors:  Heidi Barth; Christiane Schafer; Mohammed I Adah; Fuming Zhang; Robert J Linhardt; Hidenao Toyoda; Akiko Kinoshita-Toyoda; Toshihiko Toida; Toin H Van Kuppevelt; Erik Depla; Fritz Von Weizsacker; Hubert E Blum; Thomas F Baumert
Journal:  J Biol Chem       Date:  2003-07-16       Impact factor: 5.157

Review 9.  Emerging antiviral strategies to interfere with influenza virus entry.

Authors:  Evelien Vanderlinden; Lieve Naesens
Journal:  Med Res Rev       Date:  2013-06-25       Impact factor: 12.944

Review 10.  Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors.

Authors:  Andy Kilianski; Susan C Baker
Journal:  Antiviral Res       Date:  2013-11-20       Impact factor: 5.970

View more
  17 in total

1.  Nanobody-Mediated Neutralization Reveals an Achilles Heel for Norovirus.

Authors:  Anna D Koromyslova; Jessica M Devant; Turgay Kilic; Charles D Sabin; Virginie Malak; Grant S Hansman
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

2.  Atomic Structure of the Murine Norovirus Protruding Domain and Soluble CD300lf Receptor Complex.

Authors:  Turgay Kilic; Anna Koromyslova; Virginie Malak; Grant S Hansman
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

3.  Angiotensin II Promotes SARS-CoV-2 Infection via Upregulation of ACE2 in Human Bronchial Cells.

Authors:  Ilaria Caputo; Brasilina Caroccia; Ilaria Frasson; Elena Poggio; Stefania Zamberlan; Margherita Morpurgo; Teresa M Seccia; Tito Calì; Marisa Brini; Sara N Richter; Gian Paolo Rossi
Journal:  Int J Mol Sci       Date:  2022-05-04       Impact factor: 6.208

4.  Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy.

Authors:  Robert J Scarborough; Kelsey L Adams; Olivier Del Corpo; Aïcha Daher; Anne Gatignol
Journal:  J Vis Exp       Date:  2016-09-05       Impact factor: 1.355

5.  5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl)methyl]-L-proline Inhibits Hepatitis C Virus Entry.

Authors:  Lap P Nguyen; Chorong Park; Trang T D Luong; Eun-Mee Park; Dong-Hwa Choi; Kang Min Han; Han N Mai; Huu C Nguyen; Yun-Sook Lim; Soon B Hwang
Journal:  Sci Rep       Date:  2019-05-13       Impact factor: 4.379

6.  Chemovirotherapeutic Treatment Using Camptothecin Enhances Oncolytic Measles Virus-Mediated Killing of Breast Cancer Cells.

Authors:  Chen-Jei Tai; Ching-Hsuan Liu; Yu-Chi Pan; Shu Hui Wong; Cheng-Jeng Tai; Christopher D Richardson; Liang-Tzung Lin
Journal:  Sci Rep       Date:  2019-05-01       Impact factor: 4.379

7.  Identification of a clinical compound losmapimod that blocks Lassa virus entry.

Authors:  Xiaoyu Zhang; Feihu Yan; Ke Tang; Qing Chen; Jiamei Guo; Wenjun Zhu; Shihua He; Logan Banadyga; Xiangguo Qiu; Ying Guo
Journal:  Antiviral Res       Date:  2019-04-04       Impact factor: 5.970

8.  PERK Is Critical for Alphavirus Nonstructural Protein Translation.

Authors:  Bibha Dahal; Caitlin W Lehman; Ivan Akhrymuk; Nicole R Bracci; Lauren Panny; Michael D Barrera; Nishank Bhalla; Jonathan L Jacobs; Jonathan D Dinman; Kylene Kehn-Hall
Journal:  Viruses       Date:  2021-05-12       Impact factor: 5.048

9.  (4R,6S)-2-Dihydromenisdaurilide is a Butenolide that Efficiently Inhibits Hepatitis C Virus Entry.

Authors:  Chueh-Yao Chung; Ching-Hsuan Liu; Guey-Horng Wang; Alagie Jassey; Chia-Lin Li; Lei Chen; Ming-Hong Yen; Chun-Ching Lin; Liang-Tzung Lin
Journal:  Sci Rep       Date:  2016-07-18       Impact factor: 4.379

10.  Small molecules targeting coxsackievirus A16 capsid inactivate viral particles and prevent viral binding.

Authors:  Chien-Ju Lin; Ching-Hsuan Liu; Jonathan Y Wang; Chun-Ching Lin; Yi-Fang Li; Christopher D Richardson; Liang-Tzung Lin
Journal:  Emerg Microbes Infect       Date:  2018-09-26       Impact factor: 7.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.